
Ready to swing for the fences in the world of venture capital? This episode dives deep into the high-risk, high-reward realm of early-stage VC investing, where home runs, not singles, are the ultimate goal. In this engaging conversation, Scott Kelly welcomes Ed Lafferty of Saturn Partners, a seasoned investor with a wealth of experience in private equity and institutional capital. Ed shares his firm’s unique approach to funding Green Tech, FinTech, and MedTech startups, emphasizing their co-investment model and focus on backing seasoned entrepreneurs. Discover how Saturn Partners seeks alpha by targeting innovative companies in their seed and series A rounds, while also providing investors with the opportunity to participate in later-stage deals. Tune in to hear Ed’s candid insights on salesmanship in startups, the impact of AI on drug development, and why swinging for the fences is the key to creating oversized returns.
—
Watch the episode here
Listen to the podcast here
Decoding Early-Stage VC In Green, Fin, & Med Tech With Saturn Partners’ Ed Lafferty
I love talking with Ed Lafferty. We had that panel discussion that we did with him, and so he intrigued me about Saturn Partners, which is an early-stage venture capital firm focused on green tech, fintech, and medical tech. He was talking a bit about med tech when we were at the panel.
He delved into it in the interview, too. He has great insights on the industry and where it’s going, and AI and other things play into it.
He’s got a great background with private equity. He consulted for banks. He has a broader institutional capital model, as well as venture capital.
He got good training from a practical standpoint, maybe not so much from an academic standpoint. He was also with Berkshire and other high-end companies. They got to learn everything from analysis to due diligence and finance. He brings a good background from his past that he’s applying today.
This is what we’re going to hear about in the interview. That really makes it so that they have a flow through into all the next rounds and the next rounds and the next rounds because they’ve got this co-investment model that they work through.
That was good because the reality is that getting that first check is great, but you need to know there is a pathway to future funding, and the fact that he has this network of investors, and he has this broker-dealer, which provides him the opportunity to not only get people to invest in this company through the fund, but then invest directly and subsequently.
Let’s hear about Saturn Partners and Ed Lafferty.
Ed Lafferty is a partner at Saturn Partners, an early-stage venture capital firm focused on green tech, fintech, and medical tech. His career began in consulting for banks before transitioning to private equity at Berkshire Partners.
Seeking more entrepreneurial involvement, he joined Saturn Partners and helped pivot it towards specializing in seed and Series A investments within their targeted sectors.
Follow Ed Lafferty on Social: LinkedIn
About Saturn Partners
Saturn Partners focuses on early-stage (seed and Series A) investments in three key sectors: green tech, fintech, and medical tech. They aim to back seasoned entrepreneurs, particularly those with second or third startups. After the Series B round, they offer co-investment opportunities to their investors. They seek companies that improve the human condition. They also emphasize helping their portfolio companies with sales strategies and articulation. Their overall investment strategy is geared towards high-potential, high-risk ventures aiming for significant returns (“swinging for the fences”) rather than more conservative, lower-risk plays.

Ed Lafferty’s Journey Into Venture Capital
Welcome, everybody. My name is Scott Kelly. I am the founder and CEO of Black Dog Venture Partners and your host for the Emerging Managers Podcast. I’m excited to welcome a new friend, Ed Lafferty. Ed, welcome to the show.
Scott, it’s good to see you. It’s good to be with you.
Before we get to the front of what you’re doing, let’s give our audience about your background. How did you get into this? What did you do before this?
When I came out of college, I worked for a small consulting firm. We did consulting work primarily for banks. We were going to banks and teaching them how to sell. The fellow who owned the business actually shared his apartment. His apartment was on the top floor of a building that was owned by one of Berkshire Partners’ partners. I happened to network through my former boss to meet my next boss, who was a partner at Berkshire Partners. I ended up hitting it off with him.
I landed a job with Berkshire Partners and stayed there for four years, working. That’s a private equity shop that deals mostly in later-stage mid-market companies. I learned how to do a lot of financial analysis and tax analysis. There’s a lot of financial blocking and tackling. What I found out there was that I love the work, but I didn’t get to do what I really wanted to do, which is working with entrepreneurs. I love to be part of that startup community. I was working with these guys, who are all innovators. They make a lot of money, and they do some great things, but it wasn’t exactly the innovative fabric that I was looking to work with.
I met my current partner, Jeff McCormick, who is the founder of Saturn Partners. He had a broker-dealer and would raise capital for one-off deals for companies. I said, “Jeff, roll this up into a fund. Raising money is hard work. Let’s do it once instead of doing it twenty times a year.” He said, “This is probably the right time to do it.” This was in the early 2000s. He said, “The market has got some uncertainty, let’s go out and grab as much, and try to raise as much as we can.” This was pre-bubble. We closed our fund early because the bubble burst. Instead of continuing to raise, we said, “Let’s just cut it.” We started a $25 million early-stage fund, and that was in 2002. That was our first one together.
You mentioned the word sales. I’m going to touch on that in a couple of minutes because, in my opinion, that’s the lost art, especially in this generation of entrepreneurs. You lost your first fund. Let’s talk about your thesis. Let’s talk about how you invest, what you invest, and maybe some other traits of some of the investments you make.
Saturn Partners’ Core Investment Thesis: Green, Fin & Med Tech Focus
Our investment thesis has morphed over the course of time. When we started our first fund, we were generalists. I think that’s what a lot of venture capital firms back in those days were. They were generalists who were investing opportunistically. As we started to invest together, we realized that we liked doing certain deals and we were better at doing certain deals. Through our second fund, we realize that we’re going to stick to what we do best. What we do best is we’re in a very early-stage, so seed and Series A rounds.
We’re also in three different industries. We’re in green tech, fintech, and medical tech, or health tech. Those are the three things. It’s one of those things that you’re not only making a return on, but you’re also doing good. All those industries, somehow or another, relate to improving the human condition. That’s what we do now, and our thesis has developed now into those three industries, but early stage.
What we do is invest our funds through the Series B round. After the B round, we provide our investors an opportunity to co-invest with us alongside into later rounds. We create that “back up the truck” moment with 1 or 2 companies that are in our funds. A lot of our investors like that. When we pitch them initially on the fund, they want to come invest in these later deals. They like that we shake out the risks in the early stages.
A little about the thesis and stage, talk to me about the founders. What are some of the attributes of the founders that you invest in?
The founders that we invest in, as I said earlier, we like entrepreneurial guys who are out there doing it. The guys who are maybe on their second startup are our ideal guys. I think the first-time founders are great, but they need a lot more guidance. Once founders have gotten their feet wet and understand what they’re trying to accomplish, I think they’re better once they’re seasoned.
We look for founders who are second-time founders, or third-time or serial entrepreneur types. We like ones who are in an industry that they know. Maybe they came from industry and they’re in the industry, rather than people who retread, trying to shift. We don’t like people to learn on our dime. Education could be very expensive if they’re learning on your dime. That’s what we look for.
The CEO As Chief Salesperson
You mentioned sales. You work in health tech and fintech, where you’re dealing with entrepreneurs who may have good technical skills. They have good engineering skills. You touch on sales, and I believe nothing happens until you sell something. How do you perceive entrepreneurs in terms of their go-to market and actually selling what they develop? How does that play into your thoughts?
That’s a great point because we see the CEOs, and I’m sure I brought this up earlier. The CEO is the chief salesperson. They have to be able to sell their product. If they can’t sell their product or if they can develop it and not tell somebody how it works, they’re not CEO material. I think the CEO has to be the chief salesperson in the whole organization. They’ve got to be able to sell better than their chief salesperson. That’s my opinion.
The CEO must be the chief salesperson. If they can't sell their product—even if they can develop it—and explain its value, they aren't CEO material. Share on XWe helped them articulate it. A lot of times, people don’t know their pitch. They think their pitch is one thing. We have to work on them to give them that this is what your customers need to hear, not how this got developed in wherever. It’s interesting how folks who are engineering types focus on certain things, and they need to understand their customers to be able to sell it.
Going after an investor’s standpoint, if that’s your customer, the thing you want to present to them is not only how great the product is, but how much money you can make with it. I’m glad that we touched on that. You’ve been doing this for a while. You’ve got a good focus on the early stage. Do you mind sharing some success stories or some things that worked out well?
We have an early-stage investment in Constant Contact. That was one of our early Investments back before the bubble hit. It was a free market. It was one of our bigger ones. Some people may remember it. Some may not, but it was the B2B version of Amazon. We launched that a while ago. Now, we’re working on a couple of big projects that we think are going to be maybe even bigger.
We’ve been working with this company, Knopp Biosciences, which is an early-stage drug development company. We’ve been with these guys since 2002. They failed phase three in ALS, which was very unfortunate. That was in 2011. We discovered that the drug worked on something else. It works in asthma. That was just by looking at the data. We’ve pivoted the company. We had to raise new capital. A lot of our investors stuck with it, and we got some new investors in it. Now, what we did was we split the company into two companies.
We sold a license to Biohaven, which is licensing one of the drugs we had in development. It’s called Kv7. It can be used for a couple of things. Their main focus is epilepsy, but there are a couple of other projects that they’re using. We’ve got another spin-off, which is a later-stage phase-three drug, which is for asthma. That’s called Areteia Therapeutics. We’re working on both of those simultaneously, hoping for something to happen later in 2025, depending on what the public markets look like.
I was going to bring that up because there are a lot of things happening over the course of the last several months and several years, which I’ll take as a long grind to begin with. Some potential things are happening, or things that have happened recently, could have a significant impact. Where are you seeing the marketplace investing in that vertical? Getting into the deal is the easy part. Getting out of the hard part. Share some perspective on that.
The funny thing about drug development is it’s measured every time you have a phase-one, phase-two, or phase-three trial. Every phase costs a certain amount of money, so you know what you’re going to spend, which is an amazing amount of money. Hopefully, AI brings that cost down. We can talk about that later. You know what you’re being measured, and each measurement time is a time to exit, but you always make a decision. Do I stick with the company and go for the big play? How do I get out now?
You can always hit the “get out early” button and try to get out after phase one, but you are not going to get that big multiple that you’re going to get. We’ve continuously held on here, for better or for worse. I will find out. That’s part of the risk you take. That’s what we get paid for. We get paid to be a home runner. I’m not getting paid to hit singles and steal bases.
AI’s Impact On Drug Development & Healthcare
I appreciate that analogy. You mentioned AI, so I’m going to jump on that right now. AI has been around forever, but now it’s the flavor of the month. Let’s talk specifically about where you see AI impacting healthcare, medicine, and things of that nature.
Where we see it specifically, in the companies that we work with, we surely see it in fintech and environmental tech. It can create a lot of efficiencies, and it has been in there for a while. As you mentioned, it’s been under a different guise before. Now it has a new name. I’m thinking of machines and learning machines.
We see in fintech and environmental tech that AI can create a lot of efficiencies. Share on XIt’s been all these things, but we’re seeing it specifically in med tech and in the drug development because the earlier stages, where you have these animal studies, are being replaced. You can replace a lot of animal studies. There are a whole lot of reasons to replace them. Not only the cost, but also think about the environmental effects of it.
Think of all the effects on these poor puppies that they’re testing this stuff on, goats, or whatever. It depends on what they’re testing them for, but it’s not very humane. It also improves the time to market. You can run these tests much quicker and more efficiently. We’re hoping to see that get instituted in the drug development. I think we can get some outcomes a lot faster. We can get the drugs that are needed out to people quicker.
I think it should be transformational. I’m looking forward to seeing developments there. Let’s pivot a little bit. You’ve raised some money. You’ve got several LPs. Let’s talk to LPs now. Let’s talk about potential LPs and others. First of all, why don’t you give us a snapshot of who your current LPs are? Who are these people? What are their backgrounds?
We can play this into the deal flow, too, because it plays into it well. Our base is primarily high-net-worth individuals who have made their money as entrepreneurs. Many of them have invested with us, or we have backed them before. About 70% of our LPs are repeat LPs. Some of them have been entrepreneurs that we’ve backed. Some of them have been attorneys who work for entrepreneurs. We’ve got a great entrepreneur circle, and that’s part of our deal flow.
These guys are out there. They’re creating companies, they’re meeting people, they’re meeting other entrepreneurs. They see a business plan, and they call me. They say, “Ed, you’ve got to take a look at this. You’ve got to meet Scott. Scott’s got this great idea.” This is where most of our deal flow comes from. When people call this proprietary deal flow, it really is because we have the right of first refusal on the deal flow, which is great. We’ve also got a couple of pension funds, and we’ve got a few charitable organizations that are investors as well. I would say probably 80% of them are high net worth folks, family offices, and multiple family offices. Those are our guys.
It’s great to have LPs and investors in your fund that aren’t just dead money. They’re providing some value to the fund in terms of deal flow. Are these LPs in these industries? Do they provide other insights as you’re doing due diligence or post-investment?
Many of them help us with diligence. Many of them have been in the industry, and that’s why they can look at a deal and say, “You’ve got to look at this. This is the next best thing since sliced bread. I’ve seen this fail before, and these guys got the special sauce. They’ve got the right person or whatever it might be.” That’s one thing they do.
A lot of times, they also help us raise money because a lot of these guys are connected to other organizations that have capital. They’ll call us and they’ll say, “You’ve got to talk to this guy. He likes this kind of investment. I think this is right for him.” They’ll call me and stick me on them. We’ll try to sign them up as investors. Sometimes they don’t want to come in a fund. Sometimes they’ll say, “I’m not a fund guy. I’m not a fund investor. What I want to do is co-invest.” We create syndicates to invest alongside us, with some investors as well. We’ve got a broker-dealer that we still use, so we can set that up to have co-investment.
The Broker Dealer Advantage: Unique Investment Opportunities
I would touch on that. I’m glad you brought that up. Give me more about how the broker-dealer plays into what you’re doing, because not a lot of venture capital funds have a broker-dealer affiliate with them. Talk to us and everybody on the show about how that plays into what you’re doing.
Sometimes, it could be conflicting because you’re trying to raise capital for a company, and you’re trying to raise money through a fund. There is a conflict that we have to be very conscious of. We try to use it to our advantage because a lot of funds don’t have it. When we go to a company and talk to a company, we give the company the “Why us” speech.
What we say to them is, “We not only can invest and write a check in the company, but we can also expose you to a whole group of investors who may not want to invest in a fund, but maybe are interested in participating as investors in this deal, particularly.” We can go ahead and do that. We don’t take a fee on our fund, but we do take a fee on all that other. We try to keep the fee separate. We credit our investors. For anything that goes through the fund, we take a fee for it, and we credit the investors back. There’s this code inside accounting that we had to set up.
We’re trying to be fair about it to our advantage. We also use that broker-dealer at later stages. For example, this Areteia deal that we are invested in, the latest, we’re investing alongside Bain Capital and Google Ventures. This is a syndicate of later-stage investors. We called our investors and said, “Do you guys want to get in this?” They all said, yes. We set up an SPV. We use our brokerage-dealer and set up the SPV, and we invested in this later-stage deal. It’s how we follow along with our portfolio companies.
It adds another value-add opportunity for companies to raise more capital. As you said, it provides a real alternative for companies that present to you. I used to say there are more ways to skin the cat, and help some of these entrepreneurs, and find opportunities for investors. You touched on this. Now, to take a little bit of thunder away, I’m going to ask the question I always ask everybody. In the field of 3,200 venture capital funds and 1,800 fund ones, why your fund and why now?
Saturn Partners’ Strategy: Swinging For The Fences For Alpha
I’m going to go back to my baseball analogy. We are like Sammy Sosa. We are swinging for the fence with every investment that we make. We are not trying to hit singles. We’re not hitting doubles. We may strike out a lot. We’re going to have a higher strikeout record because we’re trying to make alpha. Alpha is our job. Alpha is the difference between the market returns.
We want to provide a better return. We may not do it through our fund, but we may do it in later stages because we’ll give investors the opportunity to invest later in a deal. They can back up the truck. They can invest a small amount in the fund, then invest a large amount in that one winner that comes out of the fund, and then the return to them is much greater than they would have gotten in the fund. That’s one of the big benefits we present to our investors.
What we found in our research before launching the podcast is that the alpha on these earlier-stage funds, fund ones, fund twos, fund threes, is far better than the models in the industry. For investors who want to diversify or add venture to their portfolio, look at the opportunities to get better returns. Also, for those who are advising folks, you’re finding people who are also going to be RIA advisors that are managing portfolios, or these high-net-worth people. They want to do better than the S&P. You can’t do that by buying the S&P. I’m glad that you’re swinging for the fence because for that portion of the portfolio, you need to bring up the return of the entire portfolio.
We’re not portfolio managers. Some guys try to manage a bond portfolio. That’s not what we do. I don’t have a bond portfolio to match the offset or the risks that I’m taking on the other end. This is all risk. This is all high risk. We diversify among Industries. We diversify among stages, but we don’t diversify by buying bonds or missing in finance or any of that stuff. We’re out there. We’re swinging hard.
Any final thoughts or things you want to share with the audience?
It’s one of those things that we’ve always talked about when we try to raise capital. It’s easy for funders to fund, and money managers to pick the big guy. It’s easy to pick the big guy. You go out there and pick the name brand because nobody ever got fired for using whatever. You hear that so many times, you have to, if you want to create oversized returns, you need to create a place for early-stage startup venture funds that are swinging for the fences.
This is the way you can make a difference in your portfolio and create those oversized returns. You may not get those oversized returns and some of those later-stage funds because some of those later-stage funds get into some of these investments very late. It’s almost like window dressing. Back in the old capital markets days, you used to buy stuff before the end of the quarter. If you want to create that return, look at these emerging managers because they create alpha for your portfolios.
Emerging managers really create Alpha for your portfolio. Share on XYou made a good point there because the reality is you want to be able to invest in the name brand company before they become name brand companies. How can people learn more about Saturn and you?
We have a website, SaturnPartnersVC.com. You can go there. Follow me on LinkedIn, EdLaff. I’m there too. Those are the two best places to find me. I’m in the Tampa Bay Innovation Center. I’ve been there for the last couple of years. I’ve got my office there. We moved out of Boston years ago. One of my partners is in Pittsburgh. I’m in Florida, and my other partner is in Puerto Rico. Two of us have gone for better weather. The other one is staying where he is.
I made the same decision. I’m actually a New Yorker, and now I’m in the sun with you. Ed, thanks for being on the show. For all of you out there. Make sure you like, subscribe, and share this great podcast. Again, Ed, thanks for being on the show.
It’s great to be here. Thanks for having me, Scott. Take care.
‐‐‐
Scott, I don’t know about you, but for me, I thought that the look that they had on the swinging for the fences, the home runs, not going as conservative as others do, I was surprised about because they were talking about wanting to go Series B, wanting to get all the way through to that models. I thought they would be more conservative, but he wasn’t focused on that.
I think he understands where venture capital plays in the total landscape of someone’s investing portfolio. He understands that in order to beat the S&P and in order to get that alpha, you have to swing for the fences. I love the fact that he was very honest and pragmatic. He realizes, “We have to swing for the fences. We’re going to have a bunch of strikeouts, but the handful or more of these home runs are going to give us superior returns over time.
I wish I were in his wheelhouse for the type of investments. My company is not in that type of investment. I love the two things that he says, that they looking at seasoned entrepreneurs who’ve had multiple companies, who have that, because they require less guidance and are more likely to succeed. I was like, “That’s me.”
I think he wants to deal with adults in the startup space. There’s nothing wrong with this in starting out or beginning your journey as an entrepreneur. I’ve spent the majority of my time working in that area. The reality is that if he’s working against superior returns, those returns are going to be reacting quite a bit by the management involved in their experience.
The other part that he said was about the sales emphasis. I was like, “That’s my company too.” He loved the idea of having the salesperson be the CEO. They’re being directly responsible for those sales. That’s exactly the way our company is structured. Tom Hazzard is my partner and husband, but he’s the CEO and in charge of the sales. I’m the director of AI, in charge of the tech. We have this division of labor, but that focus on sales makes us much more focused on the customer and market proof.
I love what he talked about sales. I’m not sure if it’s from a generation standpoint or a technology standpoint. Sales has become a lost art among human beings. The reality is the fact that he wants to make sure the same person who’s building the widget is selling the widget. That’s the perfect way to approach it.
I think you find out so much more about what resonates and what works. The fact that Saturn comes in and also helps articulate that pitch, focusing on the customer needs, focusing on the message, it’s going to make it easier to sell later.
Honestly, the best way to get those home runs is to make sure you get the best pitches.
That’s right. For investors looking for high-risk, high-reward opportunities, access to unique deals, and additional support beyond just capital, Saturn Partners might be the right partner for them.
Absolutely.
Exploring Co-Investment Opportunities
Tell me a little bit more about your thoughts on the co-investment opportunities, this idea that after a Series B round, there might be more opportunity for the early investors.
At some point, you and I will have a conversation, and we’ll talk about maybe the changes in the industry. Venture capital doesn’t have the same cachet it had in the past. It’s becoming like the dinosaur on how to finance companies in a lot of respects. What you are finding is private equity getting in there, individuals are getting in there using SPVs and other vehicles. I think that’s a trail that’s going to continue. The reality is this VC model, although it’s been a model forever, some of the things in how they do business are antiquated. It doesn’t jive with more sophisticated investors, new opportunities for individual investors to get involved.
I got CNBC or Bloomberg on. There are some ETFs investing in venture capital. I think there are other ways to go about it. From a venture capital standpoint, getting other people to invest, there are a couple of angles on this. I they get other people to invest in the subsequent round, they’re investing at a higher valuation, which improves the DPI of their fund. They’re able to ratchet up the balance sheet by getting other people to invest.
Do you think that a broker-dealer is a big advantage?
It can be, but he did make sure it was bounced because you had to be careful. The reality is you have to make sure that you’re vowing to the right master in business. It does provide an advantage, but he understands that you’ve got to keep church and the state separate.
It’s so intriguing. I’m so glad to get to hear Ed also talk on the panel. Tell everybody a little bit about the panel that we participated in.
Max Pog has a large virtual event that he hosts periodically. They’ve reached out to me to put together a panel of emerging managers and talked about like what we’re doing on the podcasts. We got a good opportunity to be in front of this audience, put them in front of four emerging managers, and educate them on why to invest in them and what the advantages are. I thought it was great.
There are more things that we’re going to do for these companies, these managers, as we do the interviews. The podcast is one piece. The idea is that these managers on our podcast will have opportunities like that, both online and in person. It was good to create a good audience for that. We had a great room of active people, and some good dialogue. They even emailed me after the facts. We’re so pleased about how it went versus some of the other breakout sessions.
It was so packed. It kept rotating out. I was watching the number, and it would hit the max in the room, and then it would go down a little bit, and then it would fill right back up again. Obviously, people are dying to get in, so that was a good model. I think we’ll have to be on the bigger stage next time or the bigger room. I love that.
If anyone out there is listening and thinking, “I’m an emerging manager and I should be on this show just like Ed Lafferty of Saturn Partners, then you’ve got to go to EmergingManagersPodcast.com and fill out the application that’s there. Scott will look it over, so will I, and we’ll see if you’re the right type of emerging manager for us to have a chat with.
Scott, I can’t wait till next week. We’ve got more. We’ve got so many in the queue that we’ve got to get through. We almost should speed up our publication of these, but we’re trying to keep them to one a week, so we can promote them properly as we go forward. Make sure you follow Scott and me on social media as well. We’ll be back next week with another episode.
Okay.
Important Links
- Saturn Partners
- Ed Lafferty on Saturn Partners
- Ed Lafferty on LinkedIn
- Jeff McCormick on Saturn Partners
- Berkshire Partners
- Constant Contact
- Knopp Biosciences
- Biohaven
- Areteia Therapeutics
- Black Dog Venture Partners